Efficacy of an antagonistic Anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human Non-Hodgkin's lymphoma and Hodgkin's disease.

被引：1
|
作者：
Long, Li
Patawaran, Montesa
Tong, Xia
Kantak, Seema
Aukerman, Sharon L.
Pryer, Nancy
Luqman, Mohammad
机构：
[1] Novartis Inst Biomed Res, Emeryville, CA USA
[2] LLC, XOMA US, Berkeley, CA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.230.230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
230
引用
收藏
页码：72A / 72A
页数：1
相关论文
共 50 条
  • [31] Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmice
    Mitchell R Smith
    Indira Joshi
    Fang Jin
    Coleman Obasaju
    BMC Cancer, 5
  • [32] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Tobinai, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S85 - S90
  • [33] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Kensei Tobinai
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S85 - S90
  • [34] In vitro activation of low-grade non-Hodgkin’s lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand
    C Buske
    A Twiling
    G Gogowski
    K Schreiber
    M Feuring-Buske
    GG Wulf
    W Hiddemann
    B Wörmann
    Leukemia, 1997, 11 : 1862 - 1867
  • [35] A Phase I Study of CNTO 328, An Anti-Interelukin-6 Monoclonal Antibody in Patients with A-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.
    Kurzrock, Razelle
    Fayad, Luis
    Voorhees, Peter
    Furman, Richard R.
    Lonial, Sagar
    Borghaei, Hossein
    Jagannath, Sundar
    Sokol, Lubomir
    Cornfeld, Mark
    Qi, Ming
    Jiao, Trina
    Herring, Jennifer
    Qin, Xiang
    van Rhee, Frits
    BLOOD, 2008, 112 (11) : 371 - 372
  • [36] In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand
    Buske, C
    Twiling, A
    Gogowski, G
    Schreiber, K
    FeuringBuske, M
    Wulf, GG
    Hiddemann, W
    Wormann, B
    LEUKEMIA, 1997, 11 (11) : 1862 - 1867
  • [37] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [38] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Lin Gui
    Xiaohong Han
    Xiaohui He
    Yuanyuan Song
    Jiarui Yao
    Jianliang Yang
    Peng Liu
    Yan Qin
    Shuxiang Zhang
    Weijing Zhang
    Wenlin Gai
    Liangzhi Xie
    Yuankai Shi
    Chinese Journal of Cancer Research, 2016, (02) : 197 - 208
  • [39] Rituximab (anti-CD20 monoclonal antibody) immunotherapy in patients with B-cell non-Hodgkin's lymphoma:: highly effective treatment of residual disease
    Papajík, T
    Szotkowski, T
    Raida, L
    Hubáek, J
    Faber, E
    Hlusí, A
    Vondráková, J
    Pikalová, Z
    Jedliková, K
    Jarosová, M
    Indrák, K
    LEUKEMIA, 2001, 15 (03) : 510 - 510
  • [40] Preclinical studies on yttrium-90-labeled CDR-grafted monoclonal antibody for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths, GL
    Govindan, SV
    Shih, LB
    Sharkey, RM
    Goldenberg, DM
    Hansen, HJ
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 105P - 105P
12345